Abstract
Resistance to the novel β-lactam/β-lactamase inhibitor combination ceftazidime-avibactam (CAZ-AVI) among carbapenem-resistant Enterobacteriaceae (CRE) has infrequently been reported in the United States. We report unexpectedly high rates of resistance to CAZ-AVI in CRE bloodstream isolates at our institution associated with the nonoutbreak spread of New Delhi metallo-β-lactamase in diverse Enterobacteriaceae species.
Original language | English (US) |
---|---|
Pages (from-to) | 954-958 |
Number of pages | 5 |
Journal | Clinical Infectious Diseases |
Volume | 63 |
Issue number | 7 |
DOIs | |
State | Published - Oct 1 2016 |
Keywords
- CRE
- NDM
- bacteremia
- carbapenemase
- ceftazidime-avibactam
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases